One hundred and twenty cases of enduring sexual dysfunction following treatment
Hogan, C.; Le Noury, J.; Healy, D.; Mangin, D.
International Journal of Risk & Safety in Medicine · 26(2):109-1162014
Abstract (paraphrased)
Early case series of 120 reports of enduring sexual dysfunction following drug treatment, drawn from pharmacovigilance data, helping establish the phenomenon before formal criteria existed.
Plain-language summary (paraphrased)
An early collection of 120 patient reports that first put hard numbers behind the phenomenon of sexual dysfunction that doesn't end when the prescription does — the case series that later work (including the 300-case study and diagnostic criteria) was built on.
Why it’s in the corpus
Historical foundation of the enduring-sexual-dysfunction literature; shows the signal predates recent attention.
Some fields on this page come from the release’s Markdown edition, which carries text the JSON edition omits.
Related records
- Peer-reviewed paper
Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases
Healy, David; Le Noury, Joanna; Mangin, Dee · International Journal of Risk & Safety in Medicine · 29(3-4):125-134
Drawing on reports submitted to the RxISK.org adverse-event site, the authors assembled 300 cases of persistent sexual difficulty from 37 countries after treatment with serotonin reuptake inhibiting antidepressants, finasteride-type drugs, or isotretinoin…
CROSS-0012018PFSPSSDPRSDCore corpus - Peer-reviewed paper
Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence
Healy, David; Mangin, Dee · Epidemiology and Psychiatric Sciences
Examines why PSSD incidence/prevalence remain unquantified — inconsistent coding scatters cases across health records under vague labels, blocking the large database studies needed for clear estimates.
PSSD-0132024PSSDCore corpus - Peer-reviewed paper
Citizen petition: Sexual side effects of SSRIs and SNRIs
David Healy · International Journal of Risk & Safety in Medicine
This is the published text of a citizen petition asking the US FDA to require boxed warnings and label changes for all SSRI and SNRI products regarding persistent sexual dysfunction after discontinuation. The petition marshals the history of regulatory…
LIT-0202018PSSDLiterature sweep · Oct 2026